<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - RANITIDINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>RANITIDINE</h1>

        <p><a href="../drugClass/PHP34660.html">H2-RECEPTOR ANTAGONISTS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Benign gastric ulceration</span>,
                <span class="indication">Duodenal ulceration</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg twice daily, alternatively 300 mg once daily, at night.</li>
              <li class="dose child"><strong>For children 1&#8211;5 months</strong><br/>
                1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day).</li>
              <li class="dose child"><strong>For children 6 months&#8211;2 years</strong><br/>
                2&#8211;4 mg/kg twice daily.</li>
              <li class="dose child"><strong>For children 3&#8211;11 years</strong><br/>
                2&#8211;4 mg/kg twice daily (max. per dose 150 mg).</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150 mg twice daily, alternatively 300 mg once daily, at night.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Chronic episodic dyspepsia</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">NSAID-associated gastric ulceration</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">NSAID-associated duodenal ulcer</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg twice daily for 4 weeks, to achieve a higher healing rate.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                300 mg twice daily for 4 weeks, to achieve a higher healing rate.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of NSAID-associated gastric ulcer</span>,
                <span class="indication">Prophylaxis of NSAID-associated duodenal ulcer</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg twice daily.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                300 mg twice daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Gastro-oesophageal reflux disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Moderate to severe gastro-oesophageal reflux disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                600 mg daily in 2&#8211;4 divided doses for up to 12 weeks.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                600 mg daily in 2&#8211;4 divided doses for up to 12 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Long-term treatment of healed gastro-oesophageal reflux disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg twice daily.</li>
              <li class="dose child"><strong>For children 3&#8211;11 years</strong><br/>
                2.5&#8211;5 mg/kg twice daily (max. per dose 300 mg).</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150 mg twice daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg, dose to be given at onset of labour, then 150 mg every 6 hours.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150 mg, dose to be given at onset of labour, then 150 mg every 6 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Gastric acid reduction (prophylaxis of acid aspiration) in surgical procedures</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intramuscular injection or by slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg, to be given 45&#8211;60 minutes before induction of anaesthesia, intravenous injection diluted to 20 mL and given over at least 2 minutes, alternatively (by mouth) 150 mg, to be given 2 hours before induction of anaesthesia and also when possible on the preceding evening.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of stress ulceration</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg every 8 hours, dose to be diluted to 20 mL and given over at least 2 minutes, then (by mouth) 150 mg twice daily, may be given when oral feeding commences.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Reflux oesophagitis and other conditions where gastric acid reduction is beneficial</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1&#8211;5 months</strong><br/>
                1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day).</li>
              <li class="dose child"><strong>For children 6 months&#8211;2 years</strong><br/>
                2&#8211;4 mg/kg twice daily.</li>
              <li class="dose child"><strong>For children 3&#8211;11 years</strong><br/>
                2&#8211;4 mg/kg twice daily (max. per dose 150 mg); increased to up to 5 mg/kg twice daily (max. per dose 300 mg), dose increase for severe gastro-oesophageal disease.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150 mg twice daily, alternatively 300 mg once daily, dose to be taken at night, then increased if necessary to 300 mg twice daily for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease, alternatively increased if necessary to 150 mg 4 times a day for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Conditions where reduction of gastric acidity is beneficial and oral route not available</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg every 6&#8211;8 hours.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg, dose to be diluted to 20 mL and given over at least 2 minutes; may be repeated every 6&#8211;8 hours.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid unless essential, but not known to be harmful.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Use half normal dose if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Use half normal dose if estimated glomerular filtration rate less than 50&#8239;mL/minute/1.73&#8239;m <sup>2</sup>.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>uncommon:</strong> Blurred vision,
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, interstitial nephritis, involuntary movement disorders, pancreatitis,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>slow intravenous injection</i> dilute to a concentration of 2.5&#8239;mg/mL with Glucose 5% or Sodium Chloride 0.9%; give over at least 3 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Zantac</i>
            <tm tmtype="reg"/>), give intermittently in Glucose 5% or Sodium Chloride 0.9%.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>In fat malabsorption syndrome, give oral doses 1&#8211;2 hours before food to enhance effects of pancreatic enzyme replacement.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Ranitidine for acid reflux</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux">www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux</xref>
            </p>
            </section>
      </section>






      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>
            <i>Oral</i> preparations not licensed for use in children under 3 years. </p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>
            <i>Injection</i> not licensed for use in children under 6 months.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Doses given for prophylaxis of NSAID-associated gastric or duodenal ulcer, and prophylaxis of stress ulceration, are not licensed.</p>
            </section>
      </section>








      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <p>Ranitidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks&#8217; supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity, and for the prevention of these symptoms when associated with consumption of food or drink (max. single dose 75&#8239;mg, max. daily dose 300&#8239;mg).</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of RANITIDINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,
            infusion,

            <div id="PHP76490"><a href="../medicinalForm/PHP76490.html" data-target="#PHP76490" data-action="load">Tablet</a></div>
            <div id="PHP76643"><a href="../medicinalForm/PHP76643.html" data-target="#PHP76643" data-action="load">Effervescent tablet</a></div>
            <div id="PHP76799"><a href="../medicinalForm/PHP76799.html" data-target="#PHP76799" data-action="load">Oral solution</a></div>
            <div id="PHP76567"><a href="../medicinalForm/PHP76567.html" data-target="#PHP76567" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
